Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy
Journal of The Association of Physicians of India · 2026
DOI: 10.59556/japi.74.1302 ↗At a glance
Übersichtsarbeit in Journal of The Association of Physicians of India, 2026. Written by Shashank Joshi and 13 co-authors. Institution: Consultant Endocrinologist, Department of Diabetology and Endocrinology, Lilavati Hospital and Research Center, Mumbai, Maharashtra, India, Correspon…. Major MEDLINE topics: Mineralocorticoid Receptor Antagonists, Heart Failure, Renal Insufficiency, Chronic, Diabetic Nephropathies. 41 references.
Abstract (original language)
Mineralocorticoid receptor antagonists (MRAs) are important pillars in the treatment of heart failure (HF), chronic kidney disease (CKD), and diabetic kidney disease (DKD). MRAs share complementary pathways with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with cardiovascular-kidney-metabolic (CKM) syndrome. Combination therapies of MRA with SGLT2i and GLP-1RA are showing promising results in CKM than individual therapies. Further, the unique action of MRAs in antagonizing MR receptors and aldosterone, implicated in the pathophysiology of several conditions, is paving the way for clinical trials and promising results in these therapeutic areas. Disease-specific biomarkers such as UACR and eGFR are increasingly being used to individualize treatment with MRA. Utilizing MRA-specific biomarkers may open the path for precision medicine and further treatment individualization.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Consultant Endocrinologist, Department of Diabetology and Endocrinology, Lilavati Hospital and Research Center, Mumbai, Maharashtra, India, Corresponding Author.
- Consultant Physician and Diabetologist, Department of Medicine, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
- Senior Consultant Physician, Department of Medicine, Apollo Gleneagles Hospital, Kolkata, West Bengal, India.
- Consultant Cardiologist and Programme Director, Department of Cardiology, Dr Kunhali's Heart Care Centre, Kozhikode, Kerala, India.
- Director in Interventional Cardiology and Advance HF Programme, Department of Cardiology, Fortis Hospital Okhla, New Delhi, India.
- Consultant Physician, Department of Medicine, Believers Hospital, Thiruvalla, Kerala, India.
Cite
APA
Joshi, S., Tiwaskar, M., Sharma, J., Kunhali, K., Rastogi, V., Antony, S., Nandhakumar, A. P., Vora, A., Raja, A. G., Anitha, A., Parmar, R. S., Francis, F., Sugumaran, A., & Mohanasundaram, S. (2026). Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.74.1302
Vancouver
Joshi S, Tiwaskar M, Sharma J, Kunhali K, Rastogi V, Antony S, et al. Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy. Journal of The Association of Physicians of India. 2026. doi:10.59556/japi.74.1302
BibTeX
@article{Joshi2026,
author = {Joshi, Shashank and Tiwaskar, Mangesh and Sharma, Jayanta and Kunhali, K and Rastogi, Vishal and Antony, Sunil and Nandhakumar, A P and Vora, Agam and Raja, A Ganesh and Anitha, A and Parmar, Ramkesh S and Francis, Febin and Sugumaran, Amarnath and Mohanasundaram, Senthilnathan},
title = {Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy},
journal = {Journal of The Association of Physicians of India},
year = {2026},
doi = {10.59556/japi.74.1302}
}
EUVIMED